Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8454734 | Lung Cancer | 2016 | 25 Pages |
Abstract
WBRT plus concurrent icotinib is well tolerated in EGFR-mutated NSCLC patients with brain metastases, up to an icotinib dose of 375Â mg tid. The icotinib CSF concentration seemed to have a potential ceiling effect with the dose escalation, and WBRT seemed to have no significant impact on CSF penetration of icotinib till 4 weeks after the treatment.
Keywords
high-performance liquid chromatography/tandem mass spectrometryEGFR-TKIsCISFACT-LDCRDLTBcrpIQRMMSEECoGHPLC/MS/MSMRIMagnetic resonance imagingcomputed tomographydose-limiting toxicityBBBeastern cooperative oncology groupconfidence intervalsBlood-brain barrierCSFCerebrospinal fluidinterquartile rangeMini-Mental State ExaminationEpidermal growth factor receptor tyrosine kinase inhibitors
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Lin Zhou, Jiazhuo He, Weijie Xiong, Yongmei Liu, Jing Xiang, Qin Yu, Maozhi Liang, Xiaojuan Zhou, Zhenyu Ding, Meijuan Huang, Li Ren, Jiang Zhu, Lu Li, Mei Hou, Lieming Ding, Fenlai Tan, You Lu,